Recent Company News

• 12:00 PM ET Jun 23, 2026
  

  StreetAccount Summary - U.S. Unusual Option Volume: VIX +12.9% to 19.50; S&P 500 (1.3%) to 7,378.26

• 01:14 PM ET Jun 13, 2026
  

  Genmab announces Epcoritamab Monotherapy and epcoritamab-based combination regimens demonstrate high response rates in elderly patients with newly diagnosed diffuse large b-cell lymphoma (DKK 1619.00, 0.00)

• 09:54 AM ET Jun 13, 2026
  

  Johnson & Johnson announces new TALVEY (talquetamab-tgvs) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) data that demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma ($240.87, 0.00)

• 10:48 AM ET Jun 11, 2026
  

  Genmab announces new data from post-hoc subgroup analysis from pivotal Phase 3 EPCORE FL-1 trial, evaluating epcoritamab in combination with rituximab and lenalidomide in adult patients with relapsed or refractory follicular lymphoma (DKK 1626.50, +18.50)

• 09:03 PM ET Jun 10, 2026
  

  NICE recommends Genmab's Tivdak to treat recurrent or metastatic cervical cancer that has progressed on or after systemic treatment (DKK 1608.00, 0.00)

• 08:39 PM ET Jun 08, 2026
  

  Zai Lab's TIVDAK obtains China NMPA approval for recurrent/metastatic cervical cancer ($16.48, 0.00)

• 08:05 AM ET Jun 08, 2026
  

  AbbVie highlights data from its blood cancer portfolio to be presented at EHA 2026, including data on epcoritamab (EPKINLY) ($227.23, 0.00)

• 08:24 AM ET May 29, 2026
  

  Johnson & Johnson announces new data from Phase 3 MajesTEC-9 study of TECVAYLI in patients with relapsed or refractory multiplemyeloma ($230.80, 0.00)

• 04:40 AM ET May 28, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 09:02 PM ET May 27, 2026
  

  NICE recommends Genmab's Rybrevant with carboplatin and pemetrexed for untreated advanced NSCLC with activating EGFR exon 20 insertion mutations in adults (DKK 1724.00, 0.00)